Search

everythinglearnresearchcommunity

for

Search:↓

Baricitinib, a drug for rheumatoid arthritis, atopic dermatitis, and alopecia areata, is generally safe with low risk of major side effects, even in patients with risk factors. It's also effective in promoting hair regrowth in alopecia areata patients.

INTASYL is a promising, adaptable RNAi technology for treating skin cancers.

Ritlecitinib effectively treats severe Alopecia Areata by reducing harmful immune activity in the skin.

Younger patients and those with more hair loss are less likely to benefit from oral steroid treatment for hair loss, and low vitamin D may predict relapse.

A new lotion with halobetasol and tazarotene successfully treats acne keloidalis nuchae.

Radiesse is a versatile facial injectable used for cosmetic improvements and long-term collagen production, with careful dosing needed to prevent complications.

Abrocitinib may effectively treat stubborn alopecia universalis.

Squaric acid dibutylester promotes hair growth by activating immune cells, especially macrophages.

The drug IPI-926 is safe at 160 mg daily and may help treat certain tumors, especially basal cell carcinoma.

Bevacizumab may worsen hypothyroidism, so thyroid function should be monitored during treatment.

Pulse corticosteroids help regrow hair in alopecia areata but have side effects, especially betamethasone.

Certolizumab effectively treats psoriasis and psoriatic arthritis with fewer side effects than adalimumab.

Botulinum toxin type A did not help regrow hair in severe alopecia cases.

TP0427736 may help treat hair loss by blocking a specific protein and promoting hair growth.

Switching between the medications tofacitinib and baricitinib can be effective for treating hair loss in alopecia areata.

Vitamin D3 is a safe and effective alternative to steroids for treating alopecia areata, with fewer side effects.

A woman with severe angioedema improved significantly after treatment with rituximab.

Oral Apremilast effectively treats alopecia areata in most patients.

Alisertib was found to be an effective and tolerable treatment for children with recurrent brain tumors.

Tofacitinib is somewhat effective for alopecia areata, but more research is needed on its safety and long-term effects.

Topical JAK inhibitors may help treat alopecia universalis by promoting hair regrowth.

Topical calcitriol appears safe and may reduce hair loss during chemotherapy.

Anti-TNF-α therapy may increase the risk of developing alopecia areata, especially in those with a history of autoimmune disease.

Baricitinib effectively promotes hair regrowth in both scalp and nonscalp areas for alopecia areata universalis patients.

Tofacitinib was found to be a safe and effective treatment for hair regrowth in patients with alopecia areata.

Twice-weekly 5 mg dexamethasone can effectively treat extensive alopecia areata in many patients.

Upadacitinib helps most people with alopecia regrow hair quickly and is generally safe.

Dupilumab successfully treated a woman's alopecia areata and bullous pemphigoid, leading to full hair regrowth and symptom resolution.

Bicalutamide may be a promising alternative treatment for female pattern hair loss.

A single injection of PTH–CBD can increase bone density for up to a year.